Research

• Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that affects up to 4% of the world’s population.
• HS causes painful nodules, abscesses, draining sinuses and scarring to form in body folds, including axillae, inframammary areas, groin, buttocks and others.
• Bimekizumab is an IL-17A and IL-17F inhibitor that is injected subcutaneously.
• Just under 1000 participants at approximately 220 studies centers across North America, Europe and Asia Pacific.

• Pemphigus vulgaris (PV) is a chronic autoimmune blistering disorder seen in up to 2.7/100,000 people worldwide, however PV is seen with higher frequency in New Mexico.
• PV can cause painful ulcerations on the skin and on the oral and genital mucosa.
• PRN1008 is a Bruton Tyrosine Kinase inhibitor that is taken orally
• 120 participants are enrolled worldwide
• Waiting list only

Celldex Study for exploring the safety, clinical effect, pharmacodynamics, and pharmacokinetics of CDX-0159 (barzolvolimab) in patients with Prurigo Nodularis.

https://clinicaltrials.gov/ct2/show/NCT04944862

• Prurigo Nodularis is a skin condition causing itchy areas that form bumps on the skin.
• We are studying the use of a new medication barzolvolimab to improve these skin lesions in adults.
• Status: Currently enrolling

Lichen Planus Study for evaluation of the safety and efficacy of ixekizumab in lichen planus and lichen planopilaris clinical response by Total Body Surface (TBS) determination, Investigator Global Assessment (IGA) Score, Lichen Planopilaris Activity Index (LPPAI), and Frontal Fibrosing Alopecia Severity Score (FFASS).

https://clinicaltrials.gov/ct2/show/NCT05030415

• Lichen planus and lichen planopilaris is a condition that causes itchy lesions on the skin or hairloss with itching and inflammation
• We are studying the use of an injectable medication ixekizumab in patients with this diagnosis
• Status: Currently enrolling

LITE Study for comparing the effectiveness, safety (tolerability), and duration of treatment response at 12 weeks of home versus office-based narrowband ultraviolet B phototherapy for the treatment of psoriasis. Physician Global Assessment (PGA) and Dermatology Life Quality Index (DLQI) will be used to assess effectiveness, safety (tolerability), and duration of treatment response. This is a three year pragmatic, randomized, active comparator effectiveness study.

https://clinicaltrials.gov/ct2/show/NCT03726489 

• Psoriasis is a common chronic inflammatory skin condition
• Phototherapy or light therapy can be used to improve psoriasis and is typically done in an office setting
• We are studying the use of an at home phototherapy device. Participants will be randomized to using phototherapy in the office or at home.
• Status: currently enrolling

ARQ 151-315 Study for assessing the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema).

https://clinicaltrials.gov/ct2/show/NCT04845620

• Atopic dermatitis is a condition that causes chronic itchy red skin. It is sometimes associated with allergies or asthma.
• We are looking for children ages 2-5 with moderate atopic dermatitis of the skin to enroll in a study that uses a non-steroid based topical treatment.
• Status: enrolling subjects soon

Allegro global Phase 2b/3 study for evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

https://clinicaltrials.gov/ct2/show/NCT03732807

• Alopecia areata is an autoimmune disorder that causes loss of hair.
• We are studying the use of ritlecitinib in this condition.
• Status: closed to enrollment